Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Can microRNAs improve the management of lung cancer patients? A clinician's perspective.

Tufman A, Tian F, Huber RM.

Theranostics. 2013 Dec 5;3(12):953-63. doi: 10.7150/thno.6615. Review.

2.

Biological markers in lung cancer: A clinician's perspective.

Tufman A, Huber RM.

Cancer Biomark. 2010;6(3-4):123-35. doi: 10.3233/CBM-2009-0124. Review.

PMID:
20660959
3.

Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging.

Boeri M, Sestini S, Fortunato O, Verri C, Suatoni P, Pastorino U, Sozzi G.

Expert Rev Mol Diagn. 2015 Jun;15(6):801-13. doi: 10.1586/14737159.2015.1041377. Epub 2015 Apr 30. Review.

PMID:
25924864
4.

Biomarker testing in non-small cell lung cancer: a clinician's perspective.

Bernicker E.

Arch Pathol Lab Med. 2015 Apr;139(4):448-50. doi: 10.5858/arpa.2014-0085-ED. Epub 2014 Aug 28. No abstract available.

PMID:
25166873
5.

Predictive and prognostic value of circulating tumor cell detection in lung cancer: a clinician's perspective.

Tognela A, Spring KJ, Becker T, Caixeiro NJ, Bray VJ, Yip PY, Chua W, Lim SH, de Souza P.

Crit Rev Oncol Hematol. 2015 Feb;93(2):90-102. doi: 10.1016/j.critrevonc.2014.10.001. Epub 2014 Oct 12. Review.

PMID:
25459665
6.

Biomolecular and clinical practice in malignant pleural mesothelioma and lung cancer: what thoracic surgeons should know.

Opitz I, Bueno R, Lim E, Pass H, Pastorino U, Boeri M, Rocco G; ESTS Biology Club.

Eur J Cardiothorac Surg. 2014 Oct;46(4):602-6. doi: 10.1093/ejcts/ezu048. Epub 2014 Mar 12. Review. Erratum in: Eur J Cardiothorac Surg. 2015 Jan;47(1):200.

7.

MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises.

Cortinovis D, Monica V, Pietrantonio F, Ceresoli GL, La Spina CM, Wannesson L.

Curr Pharm Des. 2014;20(24):3982-90. Review.

PMID:
24138721
8.

Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all?

Booton R, Blackhall F, Kerr K.

Thorax. 2011 Apr;66(4):273-5. doi: 10.1136/thx.2010.138370. Epub 2011 Feb 23. No abstract available.

PMID:
21345972
9.

MicroRNAs as lung cancer biomarkers.

Del Vescovo V, Grasso M, Barbareschi M, Denti MA.

World J Clin Oncol. 2014 Oct 10;5(4):604-20. doi: 10.5306/wjco.v5.i4.604. Review.

10.

MicroRNAs and lung cancers: from pathogenesis to clinical implications.

Qi J, Mu D.

Front Med. 2012 Jun;6(2):134-55. doi: 10.1007/s11684-012-0188-4. Epub 2012 Apr 18. Review.

11.

Biomarkers for personalized oncology: recent advances and future challenges.

Kalia M.

Metabolism. 2015 Mar;64(3 Suppl 1):S16-21. doi: 10.1016/j.metabol.2014.10.027. Epub 2014 Oct 30. Review.

PMID:
25468140
12.

Advances in treatment of lung cancer with targeted therapy.

Cagle PT, Chirieac LR.

Arch Pathol Lab Med. 2012 May;136(5):504-9. doi: 10.5858/arpa.2011-0618-RA. Review.

PMID:
22540298
13.

Lung cancer in the era of targeted therapy: a cytologist's perspective.

Zakowski MF.

Arch Pathol Lab Med. 2013 Dec;137(12):1816-21. doi: 10.5858/arpa.2013-0029-RA. Epub 2013 Apr 18. Review.

PMID:
23597048
14.

[Possibilities and limitations of stratified medicine based on biomarkers and targeted therapies in oncology].

Ludwig WD.

Z Evid Fortbild Qual Gesundhwes. 2012;106(1):11-22. doi: 10.1016/j.zefq.2011.12.001. Epub 2012 Jan 10. Review. German.

PMID:
22325103
15.

Real time dynamic imaging and current targeted therapies in the war on cancer: a new paradigm.

Paulmurugan R, Oronsky B, Brouse CF, Reid T, Knox S, Scicinski J.

Theranostics. 2013 May 25;3(6):437-47. doi: 10.7150/thno.5658. Print 2013. Review.

16.

Breast cancer and microRNAs: therapeutic impact.

Iorio MV, Casalini P, Piovan C, Braccioli L, Tagliabue E.

Breast. 2011 Oct;20 Suppl 3:S63-70. doi: 10.1016/S0960-9776(11)70297-1. Review.

PMID:
22015296
17.

Prognostic, therapeutic and diagnostic potential of microRNAs in non-small cell lung cancer.

Markou A, Liang Y, Lianidou E.

Clin Chem Lab Med. 2011 Oct;49(10):1591-603. doi: 10.1515/CCLM.2011.661. Epub 2011 Jul 18. Review.

PMID:
21767219
18.

Immunochemistry and lung cancer: application in diagnosis, prognosis and targeted therapy.

Nanguzgambo AB, Razack R, Louw M, Bolliger CT.

Oncology. 2011;80(3-4):247-56. doi: 10.1159/000329064. Epub 2011 Jul 6. Review.

19.

Serum microRNA 125b as a diagnostic or prognostic biomarker for advanced NSCLC patients receiving cisplatin-based chemotherapy.

Cui EH, Li HJ, Hua F, Wang B, Mao W, Feng XR, Li JY, Wang X.

Acta Pharmacol Sin. 2013 Feb;34(2):309-13. doi: 10.1038/aps.2012.125. Epub 2012 Sep 17.

20.

Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening.

Sestini S, Boeri M, Marchiano A, Pelosi G, Galeone C, Verri C, Suatoni P, Sverzellati N, La Vecchia C, Sozzi G, Pastorino U.

Oncotarget. 2015 Oct 20;6(32):32868-77. doi: 10.18632/oncotarget.5210.

Supplemental Content

Support Center